Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 5/2012

01-10-2012 | CE - LETTER TO THE EDITOR

Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis

Authors: Akira Hokama, Tetsuya Ohira, Kazuto Kishimoto, Fukunori Kinjo, Jiro Fujita

Published in: Internal and Emergency Medicine | Issue 5/2012

Login to get access

Excerpt

We have read with great interest the recent excellent review by Di Sabatino et al. [1] on ulcerative colitis (UC). We fully agree with their description that toxic megacolon is a life-threatening complication in severe UC, and that a standard plain X-ray study is useful to evaluate the degree of intestinal distension. In clinical settings, delay of surgery sometimes bears a poor prognosis when patients may not fulfill the clinical criteria for toxic megacolon by Jalan et al. [2] or definitive colonic dilatation. We recently experienced a case of ‘impending’ megacolon in a patient with UC, highlighting small bowel distension as a predictor of toxic megacolon. …
Literature
1.
Di Sabatino A, Biancheri P, Rovedatti L et al (2012) Recent advances in understanding ulcerative colitis. Intern Emerg Med 7:103–111PubMedCrossRef
2.
Jalan KN, Sircus W, Card WI et al (1969) An experience of ulcerative colitis. I. Toxic dilatation in 55 cases. Gastroenterology 57:68–82PubMed
3.
4.
Latella G, Vernia P, Viscido A et al (2002) GI distension in severe ulcerative colitis. Am J Gastroenterol 97:1169–1175PubMedCrossRef
5.
Caprilli R, Viscido A, Latella G (2007) Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 4:92–101PubMedCrossRef
Metadata
Title
Impending megacolon: small bowel distension as a predictor of toxic megacolon in ulcerative colitis
Authors
Akira Hokama
Tetsuya Ohira
Kazuto Kishimoto
Fukunori Kinjo
Jiro Fujita
Publication date
01-10-2012
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 5/2012
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-012-0834-5

Other articles of this Issue 5/2012

Internal and Emergency Medicine 5/2012 Go to the issue

CE - HEALTH TECHNOLOGY ASSESSMENT

Assessing pain in hospital in-patients: a cross-sectional study in Tuscany, Italy

IM - REVIEW

Pneumonia in frail older patients: an up to date

EM - ORIGINAL

Early antipyretic exposure does not increase mortality in patients with gram-negative severe sepsis: a retrospective cohort study

IM - ORIGINAL

Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension

IM - ORIGINAL

Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case–control study

CE - MEDICAL ILLUSTRATION

Splenic herniation after laparoscopic nephrectomy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits